___________________________________________________________________________ Colorectal Cancer 204. American Cancer Society. Colorectal Cancer Stages. Available at https://www.cancer.org/cancer/colon-rectal-cancer/detection- diagnosis-staging/staged.html. Last accessed March 7, 2022. 205. National Cancer Institute. Rectal Cancer Treatment: Health Professional Version. Available at https://www.cancer.gov/types/ colorectal/hp/rectal-treatment-pdq. Last accessed March 7, 2022. 206. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol . 2009;27(7):1130-1136. 207. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med . 2003;349(3):247-257. 208. Quasar Collaborative Group, Gray R, Barnwell J. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet . 2007;370(9604):2020-2029. 209. Kawakami H, Zaanan A, Sinicrope FA. MSI testing and its role in the management of colorectal cancer. Curr Treat Options Oncol . 2015;16(7):30. 210. Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol . 2011;29(6):610-618. 211. Ogino S, Kawasaki T, Kirkner GJ, Ohnishi M, Fuchs CS. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high. BMC Cancer . 2007;7:72. 212. Hugen N, van de Velde CJ, de Wilt JH, Nagtegaal ID. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol . 2014;25(3):651-657. 213. Chua TC, Saxena A, Chu F, Zhao J, Morris DL. Predictors of cure after hepatic resection of colorectal liver metastases: an analysis of actual 5- and 10-year survivors. J Surg Oncol . 2011;103(8):796-800. 214. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg . 1999;230(3):309-318. 215. Aggarwal C, Meropo NJ, Punt CJ, et al. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Ann Oncol . 2013;24(2):420-428. 216. Donadon M, Lleo A, Di Tommaso L, et al. The shifting paradigm of prognostic factors of colorectal liver metastases: from tumor- center to host immune-centered factors. Front Oncol . 2018;8:181. 217. Van der Jeught K, Xu HC, Li YJ, Lu XB, Ji G. Drug resistance and new therapies in colorectal cancer. World J Gastroenterol . 2018;24(34):3834-3848. 218. Angiogenesis Foundation. Update on Antiangiogenic Therapy for Metastatic Colorectal Cancer. Available at http://www.angio.org/ pdf/CRC2013ePub.pdf. Last accessed March 7, 2022. 219. Gezen C, Kement M, Altuntas YE, et al. Results after multivisceral resections of locally advanced colorectal cancers: an analysis on clinical and pathological t4 tumors. World J Surg Oncol . 2012;10:39. 220. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Colon Cancer. Available at https://www.nccn. org/professionals/physician_gls/pdf/colon.pdf. Last accessed March 7, 2022. 221. National Cancer Institute. Drugs Approved for Colon and Rectal Cancer. Available at https://www.cancer.gov/about-cancer/ treatment/drugs/colorectal. Last accessed March 7, 2022. 222. Lexicomp Online. Available at https://online.lexi.com/lco/action/login. Last accessed March 7, 2022. 223. The Angiogenesis Foundation. Treatments: Angiogenesis Inhibitors for Cancer. Available at https://angio.org/learn/treatments. Last accessed March 7, 2022. 224. U.S. Food and Drug Administration. FDA Approves First-Line Immunotherapy for Patients with MSI-H/dMMR Metastatic Colorectal Cancer. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-line-immunotherapy-patients-msi- hdmmr-metastatic-colorectal-cancer. Last accessed March 7, 2022. 225. Woo J, Palmisiano N, Tester W, Leighton JC Jr. Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer. Cancer . 2013;119(11):1941-1950. 226. Knijn N, Tol J, Punt CJ. Current issues in the targeted therapy of advanced colorectal cancer. Discov Med . 2010;9(47):328-336. 227. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature . 2012;486(7404):532-536. 228. Kim TW, Elme A, Kusic Z, et al. A phase 3 trial evaluating panitumumab plus best supportive care vs. best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer. Br J Cancer . 2016;115(10):1206-1214. 229. Peeters M, Oliner KS, Price TJ, et al. Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clin Cancer Res . 2015;21(24):5469-5479. 230. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Rectal Cancer. Available at https://www.nccn. org/professionals/physician_gls/pdf/rectal.pdf. Last accessed March 7, 2022.
Powered by FlippingBook